BPI: Brief Pain Inventory · chronic pain in MS
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Short‐term improvement Scale used (range; lower is better): Clinical Global Impression (1 to 7) Agoraphobic Cognitions Questionnaire (1 to 70) Panic Disorder Severity Scale (0 to 28) Brief Scale for Anxiety (0 to 60) · adults with panic disorder
1 finding from 1 review
Anxiety (state) · adults with panic disorder
1 finding from 1 review
Short‐term improvement Scale used (range; lower is better): panic frequency Clinical Global Impression (1 to 7) Agoraphobic Cognitive Questionnaire (1 to 70) Fear Questionnaire Agoraphobia Subscale (0 to 14) Brief Scale for Anxiety (0 to 60) STAI ... · adults with panic disorder
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) showed no clear difference in brief Pain Inventory (BPI) - pain intensity, change from baseline compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Brief Pain Inventory (BPI) - pain interference, change from baseline · Adults (>18 years) with temporomandibular joint osteoarthritis (TMJ OA) diagnosed by RDC/TMD or compatible criteria
Glucosamine sulfate (oral) showed no clear difference in brief Pain Inventory (BPI) - pain interference, change from baseline compared with ibuprofen (oral); GRADE not reported.
1 finding from 1 review
Intervention not reported
Prevalence of psychological trauma (short term: up to 3 months postpartum) Measured by various scales ‐ Impact of Event Scale (IES), MINI‐PTSD · Women of any age who had given birth within one month of the intervention being offered
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Prevalence of depression or depressive symptoms (short term: up to 3 months postpartum) Measured by various scales ‐ EPDS, HADS · Women of any age who had given birth within one month of the intervention being offered
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Prevalence of anxiety (short term: up to 3 months postpartum) Measured by HADS · Women of any age who had given birth within one month of the intervention being offered
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Prevalence of fear of childbirth (short term: up to 3 months postpartum) · Women of any age who had given birth within one month of the intervention being offered
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Prevalence of general psychological morbidity (short term: up to 3 months postpartum) · Women of any age who had given birth within one month of the intervention being offered
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health service utilization (short term: up to 3 months postpartum) · Women of any age who had given birth within one month of the intervention being offered
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Attrition from treatment (short term: up to 3 months postpartum) · Women of any age who had given birth within one month of the intervention being offered
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Total studies: 42 Total participants: 14,626 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
The intervention led to lower total studies: 42 Total participants: 14,626; GRADE not reported.
1 finding from 1 review
no estimate extracted
42 participants
GRADE not reported
Intervention not reported
Desvenlafaxine high dose RCTs: 2 Participants: 870 · people with chronic pain Interventions: desvenlafaxine high dose (≥ 50 mg); duloxetine low dose (< 60 mg), standard dose (60 mg), and high…
1 finding from 1 review
no estimate extracted
2 participants
Very low
Intervention not reported
Total studies: 50 Total participants: 14,926 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
50 participants
GRADE not reported
Intervention not reported
Duloxetine high dose RCTs: 14 Participants: 3683 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
14 participants
Low
Intervention not reported
Duloxetine standard dose RCTs: 18 Participants: 4959 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
18 participants
Moderate
Intervention not reported
Milnacipran high dose RCTs: 2 Participants: 1670 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
2 participants
Low
Intervention not reported
Milnacipran standard dose RCTs: 4 Participants: 1866 · people with chronic pain Interventions: duloxetine low dose (< 60 mg), standard dose (60 mg), and high dose (> 60 mg); milnacipran…
1 finding from 1 review
no estimate extracted
4 participants
Moderate